A5070289715- Diabetes Treatment and Management
- Diabetes Management and Research
- Metabolism, Diabetes, and Cancer
- Pancreatic function and diabetes
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pharmacology and Obesity Treatment
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes Management and Education
- Diabetes and associated disorders
- Diet and metabolism studies
- Medication Adherence and Compliance
- Pharmaceutical studies and practices
- Chronic Disease Management Strategies
- Primary Care and Health Outcomes
- Inhalation and Respiratory Drug Delivery
- Health Systems, Economic Evaluations, Quality of Life
- Schizophrenia research and treatment
- Clinical practice guidelines implementation
- Adenosine and Purinergic Signaling
- Adipose Tissue and Metabolism
- Healthcare Systems and Technology
- Pharmaceutical Practices and Patient Outcomes
- Hormonal Regulation and Hypertension
- Pituitary Gland Disorders and Treatments
- Heart Failure Treatment and Management
Ochsner Health System
2008-2024
Ochsner Medical Center
2013-2022
Blackburn College
2020
Bridgewater College
2019
Hyattsville Community Development Corporation
2018
American Association of Clinical Endocrinologists
2013-2017
Ibero American University
2015
University of New Orleans
2012-2014
Raritan Bay Medical Center
2013-2014
Manitoba Beekeepers' Association
2014
OBJECTIVE To determine the efficacy and safety of liraglutide (a glucagon-like peptide-1 receptor agonist) when added to metformin rosiglitazone in type 2 diabetes. RESEARCH DESIGN AND METHODS This 26-week, double-blind, placebo-controlled, parallel-group trial randomized 533 subjects (1:1:1) once-daily (1.2 or 1.8 mg) placebo combination with (1 g twice daily) (4 mg daily). Subjects had diabetes, A1C 7–11% (previous oral antidiabetes drug [OAD] monotherapy ≥3 months) 7–10% OAD therapy...
Aim: Exenatide, an incretin mimetic for the adjunct treatment of type 2 diabetes (DM2), reduced A1C and weight in 30‐week placebo‐controlled trials. This analysis examined effects exenatide on glycaemic control over 82‐week period patients with DM2 unable to achieve adequate sulphonylurea (SU) and/or metformin (MET). Methods: interim is 314 who received trials subsequently 52 weeks open‐label uncontrolled extension studies 82 total. Patients continued their SU MET regimens throughout....
The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy safety of varying daily injection degludec (IDeg), an ultra-long-acting insulin.This 26-week, open-label, treat-to-target enrolled adults (≥18 years) with type 2 diabetes who were either naïve receiving oral antidiabetic drugs (OADs) (HbA(1c) = 7-11%) or previously on ± OAD(s) 7-10%). Participants randomized 1) once-daily...
OBJECTIVE— Glycemic control using inhaled, dry-powder insulin plus a single injection of long-acting was compared with conventional regimen in patients type 2 diabetes, which previously managed at least two daily injections. RESEARCH DESIGN AND METHODS— Patients were randomized to 6 months’ treatment either premeal inhaled bedtime dose Ultralente (n = 149) or injections subcutaneous (mixed regular/NPH insulin; n 150). The primary efficacy end point the change HbA1c from baseline study....